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negative and there is a strong suspicion of AICH, anti-LKM
antibodies or positive tests for HCV may suggest type 2
AICH.
In the absence of other positive results metabolic
disorders must be excluded. Serum copper, urinary copper
excretion and plasma caeruloplasmin will help to exclude
Nilson's disease. Serum ferritin and transferrin and a,-
.3.ntitrypsin levels should be determined to exclude iron
storage diseases and a,-antitrypsin deficiency.
In most instances liver biopsy is important. An adequate
:ore is essential to ensure that sufficie.nt representative
-issue is present for a valid assessment to be made. Biopsies
should be interpreted by an experienced pathologist to
Nhom all the patient's clinical and biochemical findings
should be available. Immunohistochemical techniques can
"Je important in confirming a diagnosis; where such expertise
s absent, the specimen should be sent to a centre of
excellence for review. The block itself should accompany the
slides so that further preparation is possible.
Where all diagnostic approaches fail to define an obvious
cause, a 'non-diagnosis' of cryptogenic CH may have to be
llade. It is, however, important to remember that HCV
Infection, HBV infection and AICH will in some cases fail to
yield definitively positive results. Here a trial of steroids
should be undertaken, under strict supervision since viral
CH may advance rapidly on steroid therapy.
In all but the most straightforward cases patients may
benefit from review by a specialist centre interested in liver
disease. It is our experience that many patients referred to
the Liver Clinic of the University of Cape Town for
consideration of a transplant for apparently 'end-stage' liver
disease have on review turned out to have diseases
amenable to medical therapy; in many instances this has
made surgery unnecessary.
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Chronic viral hepatitis caused by hepatitis B, C or 0 may
lead to cirrhosis, hepatocellular failure and hepatocellular
carcinoma. The morbidity of these diseases has
necessitated a prolonged search for effective therapy.
Although many antiviral compounds have been evaluated for
the treatment of chronic viral hepatitis, few have achieved
clinical applicability. Alpha-interferon has been widely
studied, and remains the mainstay of treatment. A number
of other cytokines, including thymosin, are being evaluated.
Nucleoside analogues, alone or in combination with alpha-
interferon, may prove useful adjuncts to the treatment of
chronic hepatitis Band C.
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G. M. Dusheiko. M.B. B.CH.• EC.P. (SA). ERC.P.
SAMJ Volume 84 No.8 August 1994
Antiviral treatment of hepatitis 8
Hepatitis B is caused by the hepatitis B virus (HBV), a large
(42 nm) enveloped DNA virus that infects the liver, causing
hepatocellular necrosis and inflammation. The infection can
be either acute or chronic, and can range in severity from an
asymptomatic infection that resolves completely, to a
severe, symptomatic infection with progressive and even
fatal illness. Some patients with chronic hepatitis B have a
remission in disease, marked by disappearance of HBV DNA
and HBeAg from serum with improvement in serum
aminotransferase activity despite persistence of HBsAg.
Measurement of serum HBV DNA in patients with chronic
hepatitis B by polymerase chain reaction (PGR)
demonstrates that the loss of HBeAg is associated with a
decreased rather than complete clearance of HBV DNA in
the serum.' Other patients lose HBeAg or are anti-HBe
positive, yet have active liver disease and HBV DNA
detectable in serum by dot or blot hybridisation techniques.
These patients have been shown to be infected with an HBV
mutant, with a nucleotide substitution in the pre-core region
of the genome!"
Antiviral therapy for chronic
hepatitis B
Interventional treatment of chronic hepatitis B is targeted at
patients with active disease and viral replication, preferably
at a stage before signs and symptoms of cirrhosis or
significant injury have occurred. Eradication of the infection
is possible in only a minority of patients. Permanent loss of
HBV DNA and HBeAg is considered a response to antiviral
treatment, as this result is associated with an improvement
in necro-inflammatory damage and reduced infectivity. It is
possible, but unproven, that the accompanying reduction in
histological chronic active hepatitis lessens the risk of
cirrhosis and hepatocellular carcinoma. HBV DNA may still
be detectable in serum and liver after loss of HBeAg and
HBsAg induced by antiviral therapy, but this is often not
associated with progressive disease.'
Alpha-interferon
The interferons are a family of related proteins. There are
four main groups: alpha, beta, omega and gamma. There are
at least 24 interferon-alpha genes but only single beta and
gamma genes. Interferon-alpha-1 (alpha and gamma) genes
code for 165-166 amino acids. Type 11 (gamma) interferon
genes code for 174 amino acids. Interferon-alpha and
gamma are induced in most nucleated cells in response to
virus infection or to double-stranded RNA (ds RNA). They
act via a common surface receptor.
Recombinant and Iymphoblastoid interferons are available
for therapeutic use. Therapy for hepatitis B has now become
possible with the demonstration that alpha interferons inhibit
HBV replication and that prolonged therapy can lead to a
remission in disease, although the mechanism of action of
interferons in chronic hepatitis B infection is not known.
Unfortunately, interferon therapy of chronic hepatitis is
effective in fewer than 50% of cases of chronic hepatitis B,
is relatively expensive, requires administration by injection, is
often confusing in its effects, and is not without side-effects.
Nonetheless, recombinant interferon has been licensed for
treatment of chronic hepatitis B in many countries.
Antiviral mechanisms of
interferons
Interferons interfere with several stages of the viral life cycle,
although the actual mechanism varies with different viruses.
They induce several enzymes and proteins, the best.
characterised of which are the 2'5'-0Iigo-adenylate
synthetases (2'S'-A synthetases). ds RNA-dependent protein
kinases and the Mx system.
Other antiviral mechanisms include the activation of
expression of the class I major histocompatibility antigen
(MHC) genes by all interferons, and those of the class 11 by
gamma interferon, to increase and enhance the expression
of MHC at the cell surface, and thereby amplify viral antigen
recognition and display. Interferons also modify the cellular
and humoral immune response; expression and activation of
natural killer cells and T Iymphocytes are affected. Early and
late events in the viral life cycle, such as uncoating of
viruses or integration of proviral DNA, are modified by
interferons.
Viruses may decrease interferon production from infected
cells, and certain viruses may have evolved mechanisms of
inhibition of interferon production.5 It has indeed been
suggested that a rationale for interferon treatment of chronic
hepatitis B is a relative defect in adult carriers in the
production or action of interferon, or an inhibition by
hepatitis B of the activation of the interferon system.S.7 In
particular, interferon is not detectable in the serum of
patients chronically infected with HSV.
Therapeutic use of alpha-
interferon in chronic hepatitis 8
Alpha, beta and gamma interferons were recombinantly
cloned and became available for therapeutic use after 1981.
Three preparations of alpha-interferon are currently
available, two of which are recombinant (Roferon A, alpha-
2a, Hoffmann La Roche) (Intron A, alpha-2b, Schering), and
one of which is prepared from a Iymphoblastoid cell line
(Wellferon, alpha n1, BUrrfJughs Wellcome). Alpha-2a and 2b
are recombinant preparations produced in Escherichia coli.
Alpha-2a has a lysine molecule at position 23 instead of the
arginine present in alpha-2b. Alpha-n1 is a natural mixture of
interferon-alpha produced by human Iymphoblastoid cells
after viral stimulation. Early pilot studies pointed out the
inhibitory effect of recombinant alpha-2a interferon upon
HBV replication and the therapeutic potential of this drug·
Later, in controlled dose-finding studies, predictors of
response could be tentatively defined, dose ranges narrowed
and therapeutic strategies outlined." Approximately 35 - 45%
of patients treated with 5 - 10 MU three times weekly for 6
months become negative for HBeAg.
Response rates in most of the early studies were higher in
carriers with higher baseline serum aminotransferase levels
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than in those without elevated aminotransferase levels. The
subclinical exacerbation of the hepatitis frequently seen in
responders suggests that interferon acts by augmenting the
,mmune response to HBV, perhaps triggered by the
nhibition of viral replication as well as the effects of
.nterferon on cytotoxic T cells.
Based on the data obtained from these studies,
ndications for treatment and definitions of response can be
ormulated. '°The immediate goal of therapy is to eradicate
liral replication and ameliorate the underlying liver disease.
'1ecommendations for therapy should be cautious, because
herapy is effective in only 30 - 50% of patients, the optimal
Jose and duration of therapy remain unclear, and side-
3ffects can be problematic. Alpha-interferon therapy is,
lowever, indicated in patients with typical chronic hepatitis B
,vho have HBsAg in serum with HBeAg and/or HBV DNA
clnd raised aminotransferase activity (at least twice the upper
imit of normal). Patients with HBsAg without HBV DNA in
3erum should not be treated, as alpha-interferon has no
3ffect on HBsAg alone. A response to alpha-interferon is
jefined by a loss of HBV DNA and HBeAg from serum, fall
of serum aminotransferase activities into the normal range
3.nd subsequent improvement in liver histology.
Measurement of HBV DNA can be quantitated, but is not
standardised." HBeAg may not become undetectable for
some months after HBV DNA is negative. Although residual
HBV DNA can be detected by PCR in serum, the disease
appears to be ameliorated.' Approximately 20% of patients
who respond to treatment with clearance of HBeAg will also
clear HBsAg within a year of therapy, and up to 65% may
later clear HBsAG after 6 years of follow-up.12
Response is generally associated with histological
reduction in inflammation. Although parameters that predict
responsive patients are difficult to characterise fully, the
following may respond more favourably: women, those
carriers with elevated pre-treatment serum aminotransferase
levels, those with chronic active hepatitis, those with lower
serum HBV DNA, those negative for anti-HIV, those with a
history of hepatitis, whites with more recent onset of
disease, with IgM anti-HBc, increased expression of cyto-
adhesion molecules'and activation of the interferon systems
as measured by 2'5'-0Iigo-adenylate synthetase."'" HIV-
positive patients tend to have higher levels of HBV
replication" and are less responsive. Although these factors
provide some predictive information, none of these criteria is
absolute and individual carriers, e.g. ethnic Chinese with
active disease or those patients with anti-HIV but normal
CD4 Iymphocyte counts, may respond, making the
prediction of treatment outcome somewhat difficult.
The appropriate dose of interferon is not yet established,
but 5 - 10 MU three times weekly, or 4,5 - 5 MU daily given
subcutaneously or intramuscularly for 4 months is currently
prescribed.
The major early side-effects of interferon include an
influenza-like syndrome, chills, fever, malaise, muscle aches
and rigors. Later side-effects include malaise, muscle aches,
headaches, poor appetite, weight loss, increased need for
sleep, psychological effects, (irritability, anxiety, depression)
hair loss, thrombocytopenia and leukopenia. Unusual or
severe side-effects include seizures, acute psychosis,
bacterial infections, auto-immune reactions, thyroid disease,
proteinuria, myocardiopathy, skin rashes and interferon
antibodies. Patients should be monitored at 1 - 4-weekly
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intervals during treatment and blood counts and serum
aminotransferase activity should be measured at these
intervals. HBV DNA and HBeAg should be measured
monthly to monitor the progress of treatment. Thyroid
functions should be measured before, during and at the end
of therapy. 16-19 There are recent reports of interstitial lung
disease in patients treated with higher doses of alpha-
interferon.
The role of interferon antibodies in reducing response is
controversial, but neutralising of antibodies may be one
variable which affects response to interferon. A higher
proportion of patients with chronic hepatitis (20%) treated
with alpha-2a develop neutralising antibody (20% v. 6,9% v.
1,2% among patients treated with alpha-n1). Thus
interferon-alpha-2a may be more immunogenic20.21 In some
patients loss of efficacy or 'breakthrough' may correlate with
antibodies, and a neutralising effect may be responsible in
some patients who have a breakthrough after an initial
response, and in whom response occurs after treatment with
an alternative interferon. However, it is still difficult to draw
firm conclusions about the clinical significance of interferon
antibodies. The patients treated are often heterogeneous,
other factors affect the response and patients may respond
despite developing antibodies. There are also different
assays for measuring antibodies including immuno-assay,
immunoradiometric assays, and antiviral neutralisation bio-
assays.
Patients who do not respond to therapy with alpha-
interferon represent a difficult management problem. Lower
doses given for a longer period are currently being studied.
The prescription of alpha-interferon is also limited by its
relatively high cost, but an economic evaluation of the
'relative costs of alpha-interferon and chronic hepatitis B
suggests that some benefit can be obtained. 22
Treatment of special groups of
patients with hepatitis B
Patients with anti-HBe-positive chronic
hepatitis
Patients who are anti-HBe positive but who have HBcAg in
hepatocytes and histological chronic active hepatitis due to
infection with HBV pre-core mutants affecting the
expression of HBeAg may have severe disease. In parts of
Europe and elsewhere, disease caused by this variant of
hepatitis B is more common than disease caused by the
'wild type' of HBeAg-positive chronic hepatitis.
Approximately 25% of patients have long-term responses."
In a trial of interferon-alpha-2a therapy with 9 MU given
intramuscularly three times weekly for 16 weeks, 33% of
anti-HBe-positive carriers lost HBcAg, compared with none
of the controls. In a second study of Iymphoblastoid
interferon (5 MU/m2 for 6 months) in 30 patients, at 18
months, 53% of the treated patients had responded v. 17%
of the controls.2' Histological improvement was seen in 53%
and HBcAg disappeared in 66%, compared with 33% of
untreated patients. Longer-term evaluation has indicated
that patients have tended to relapse with time. Thus
although response rates are high, many patients relapse
when treatment is stopped.
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2'3'-dideoxyguansine (ddG), 2',3' -dideoxyinosine (ddl),
3'-azido-2' dideoxythymidine (An)
Adenine arabinoside












Steroid withdrawal and acyclovir
New experimental nucleoside analogues
2' -fluorinated pyrimidine arabinosyl furanosides
2,6, diaminopurine 2' ,3', dideoxyriboside
2' ,3' -dideoxy-3' -fluorothymidine (FddThd), 2' ,3' -dideoxy-3'-
fluoro-5-methylcytidine (FddMeCyt), 2', 3'-dideoxy-3'-fluoro-
5-ethylcytidine (FddEtCyt),
The 2'-fluorinated arabinosyl-pyrimidine nucleosides: FIAC,
FMAU
Famciclovir
2' ,3'-dideoxy-3'-thiacytidine ((±)-SddC) (Lamuvidine)
(2' -deoxy-3' -thia-5-fluorocytosine (FTC))
Purine nucleoside analogues (cyclobut A and cyclobut G) with
cyclobutane rings
Hand (+) enantiomers of cis-5-fluoro-1- (2-(hydroxymethyl)-1,
3-oxathiolan-5-yl) cytosine
erythromycin A-9-methyloxime (EMO) and other oxime
derivatives of erythromycin A
Other modalities
Antisense oligodeoxyribonucleotides
Synthetic oligodeoxynucleotide coding for ribozyme motifs
Treatment of children
Asian children, or other children who are infected perinatally,
have mild disease activity and respond poorly to interferon
treatmenU5 They appear to be profoundly tolerant of HBV,
perhaps as a result of developing tolerance to HBeAg in the
neonatal thymus, and thereby impairing the clonal T cell
response to HBV.26 In contrast, children with active disease
and high serum aminotransferase levels respond to
interferon therapy similarly to adults and usually accept
treatment well!,,28 The appropriate dose of interferon in
children is 5 MU/m2 subcutaneously three times weekly for 4
months.
Oriental patients
Prospective studies have shown that Asians have a low rate
of response to alpha-interferon and frequently reiapse. 25.29
For these reasons, alpha-interferon therapy should be
limited to those Oriental patients with active disease and
elevations in serum aminotransferase levels. Furthermore,
these patients should be treated only after explanation of
the low possibility of response. Patients with active disease
may respond to corticosteroid withdrawal and interferon; in
a preliminary report, up to 50% of patients with elevated ALT
cleared HBeAg'"o
Patients with advanced cirrhosis
Patients with cirrhosis and ascites, encephalopathy or
persistent jaundice from chronic hepatitis B have a dire
prognosis without treatment, but are prone to developing
multiple, serious side-effects from higher doses (2 - 10 MU)
of alpha-interferon, particularly bone marrow suppression,
neutropenia and an increased incidence of serious bacterial
infections. Low doses of"interferon 1- 3 MU three times a
week could be considered in these patients." This treatment
should be administered cautiously, and only by physicians
with experience of interferon, who can monitor the patients
weekly, and where liver transplantation is available~.
Therapeutic trials of low doses of alpha-interferori in such
patients are in progress.
Immunosuppressed patients
Chronic hepatitis B is common among patients on renal
dialysis, patients with malignancies receiving chemotherapy
and patients who have had kidney, heart or liver transplants.
Anecdotal experience suggests that interferon has little
effect in patients with major immune deficiencies.29
Retrospective analyses have suggested that patients with
anti-HIV do not respond to interferon as well as non-HIV-
infected patients. However, good responses may occur in
some patients with anti-HIV but normal peripheral CD4 T
Iymphocyte counts, so that perhaps anti-HIV alone should
not exclude a patient from therapy.
Patients with extrahepatic disease
Glomerulonephritis caused by chronic HBV has been treated
with recombinant interferon-alpha-2b at a dose of 5 million
units SUbcutaneously daily.33 In patients in whom HBeAg
disappeared and aminotransferase levels fell within the
normal range, urine protein excretion also decreased and
glomerulonephritis resolved.
Other antiviral agents for
chronic hepatitis B
Other antiviral therapies for chronic hepatitis B have made
use of a variety of agents. These include the fOllowing.
Currently used nucleoside analogues
Antiretroviral therapies used in HIV infection have been
tested in chronic hepatitis B. Both these viruses contain a
reverse transcriptase. Initial experiments in hepatoblastoma
cells transfected with hepatitis B (hepG2) suggested that
2'3'-dideoxyguansine (ddG), 2'3'-dideoxyinosine (ddl) and
3'-azido-2'dideoxythymidine (AZT) diminished HBV
replication by suppressing reverse transcription in the
replicative cycle. 33 However, their usefulness in patients is
limited.
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Adenine arabinoside is an analogue of adenine, and a
potent inhibitor of HBV DNA polymerase. Adenine
arabinoside 5'-monophosphate (ara-AMP), a water-soluble
congener, can be administered intramuscularly. Suppression
af HBV DNA has been demonstrated and clearance of
rlBeAg in 33% of patients were achieved in recent
controlled trials. Usually 8 weeks of treatment are required
'0 effeCt loss of HBeAg and HBV DNA, but in many cases,
3erious neurotoxicity is seen after 4 weeks. Although the
jrug is a potent inhibitor of hepatitis B virus, its future as
3ingle-agent therapy for chronic hepatitis B is uncertain.
!\ntiviral therapy with ara-AMP may be effective in
3uppressing the disease activity and improving survival in
.)atients with polyarteritis.34
Ara-AMP conjugated with lactosaminated albumin, a
jalactosyl-terminating neoglycoprotein which selectively
;:>enetrates into hepatocytes by receptor-mediated
3ndocytosis, inhibited virus replication in patients with HBV
'nfection and woodchucks with chronic WHY infection. Free
3nd conjugated ara-AMP were active at doses of 10 mg/kg
and 0,75 mg/kg respectively.35 This strategy may reduce the
dose related side-effects; however, the compound is not
generally available. Hepatocyte vacuoles caused by swelling
of secondary Iysosomes have been reported in cases where
high doses of the conjugate were administered to
experimental animals.3•
Levamisole, an anti-helminthic, has been claimed to
inhibit HBV replication in up to 60% of patients.37 However, it
has not yet been established whether the initial good results
have proved reproducible. A combined trial of
Iymphoblastoid interferon (5 MU/m' plus levamisole (150 mg
three times per week)) revealed a higher response rate (38%)
in patients treated with interferon alone compared with those
treated with the combination (10%). Thus levamisole has no
added benefit when combined with alpha-interferon.38
Thymosin is an immune stimulant known to enhance
suppressor T-cell activity and in vitro B-cell synthesis of IgG.
Peptide preparations of thymosin have been evaluated in
small controlled trials, and HBV DNA has been noted to
become negative in some of these patients, as well as in
chimpanzees with chronic hepatitis B.39 It is given
parenterally. This interesting agent's possible therapeutic
role is now being evaluated in a larger controlled trial. The
drug has few side-effects, and may prove to be an
alternative to alpha-interferon.
Combination therapies
Pulsed corticosteroid treatment and
interferon
A multi-centre trial comparing the efficacy of prednisolone
withdrawal plus interferon (alpha-2b) to interferon alone
(5 MU daily for 16 weeks) has not shown any added benefit
from corticosteroids plus interferon: 38% of patients in both
groups lost HBeAg, and 12% and 10% respectively lost
HBsAg.40 However, the response rates with combined
treatment were better than interferon alone in those patients
with pre-treatment serum ALT less than 100 IU/I (44% v.
18%). These data could mean that 'unprimed' carriers, with
inactive disease, who are poorly responsive, are rendered
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more responsive by prior activation with corticosteroid
withdrawal. The investigators also showed that carriers with
lower concentrations of HBV DNA «100 pg/m!) were more
likely to respond to treatment. This treatment regimen
should not be used in patients with decompensated
hepatitis B because of the risk of inducing severe hepatic
necrosis.
New nucleoside analogues
The in vitro and in vivo antiviral effects of new purine and
pyrimidine antiviral nucleoside analogues are currently a
major research focus. This research has recently suffered a
major setback with reports of lethal toxicity in patients with
chronic hepatitis B treated with fialuridine. The preliminary
findings point to a possible association of mitrochondrial
toxicity with this and other nucleoside analogues." The
search therefore continues for safe drugs for the treatment
of hepatitis B. There are several other promising and
possibly safer drugs now being investigated, including drugs
with less activity against mitochondrial gamma polymerase,
for example 3-thiacytidine or famciclovir." Their efficacy is
presently unproven: chronic type B hepatitis disease will
require relatively long courses of treatment, and many of
these antiviral drugs may require activation of the immune
response for eradication of HBY.
Antiviral treatment of HeV
Newer tests for diagnosis of hepatitis C include detection of
antibodies to several recombinantly expressed HCV
antigens, or peptides (c100-3, c22, c33, c200, NS5) and
detection of HCV RNA in serum by polymerase chain
reaction amplification. Several isolates of hepatitis C have
been cloned. The sequence divergence of these isolates of
hepatitis C have been cloned. The sequence divergence of
these isolates indicates that there are several major
genotypes (serotypes) of hepatitis C and component
subtypes.'3.44 Geographical localisation of these types has
been reported.
The natural history of the disease is uncertain. The virus
has a disturbing propensity to cause chronic infection, and it
is believed that 10 - 20% of patients with chronic hepatitis C
infections will progress to cirrhosis within a decade. The risk
of further progression is probably cumulative, but is
influenced by other co-factors which include viral genotype,
level of viraemia, other viral infection, immunosuppression,
age of acquisition, alcohol and perhaps parasitic disease.
The infection causes systemic disease and may be
associated with a number of systemic complications,
including a form of auto-immune hepatitis,
cryoglobulinaemia, porphyria cutanea tarda, lymphocytic
sialedinitis and membranous glomerulonephritis.
There are conflicting reports regarding the occurrence of
hepatitis C antibodies in patients with auto-immune liver
disease. Clearly the ELlSA for anti-HCV is prone to false
positive results in patients with high concentrations of
immunoglobulins in serum.'5.46 However, in some countries,
patients with type 11 auto-immune chronic active hepatitis
appear to have a high frequency of genuine exposure to
HCV, and antibodies to liver and kidney microsomal
antibodies are present in patients."·4. These patients may
SAMJ Volume 84 No.8 August 1994
also have circulating antibodies to a pentadecapeptide
(Gor), an epitope of normal hepatocytes; this phenomenon
may represent an auto-immune response peculiar to type C
hepatitis!9 This association has some therapeutic
implications - in some of these patients the disease may
be aggravated by alpha-interferon and responsive to
corticosteroids.
Therapy of chronic hepatitis C
Chronic hepatitis is a common consequence of community-
acquired hepatitis C infection in patients who may not have
suspected exposure to the virus. Prospective studies have
suggested that 10 - 20% of patients with chronic NANB
hepatitis develop cirrhosis within a 10-year period.
Individuals with chronic hepatitis C with elevated ALT and
histological evidence of chronic active hepatitis should
therefore be considered for antiviral therapy. Asymptomatic
patients detected through blood screening will require a
supplement test to verify their HCV status, as the rate of
false positive anti-HCV tests in low-risk donors is high.
Ideally HCV RNA should be measured in all patients to
confirm viraemia, but the test is not generally available for
routine diagnosis. If the test is reproducibly positive, then
levels of serum aminotransferases, bilirubin and alkaline
phosphatase, and prothrombin time should be measured in
referred blood donors. In patients whose lifestyle or
geographic origin suggests that they are at risk of other
forms of viral hepatitis, HBsAg and HIV infection also need
to be considered. Because auto-immune hepatitis is treated
differently, it is particularly advisable to exclude this
diagnosis by measuring the titres of anti-smooth muscle and
anti-liver kidney microsomal antibodies, even in those with a
positive anti-HCV test, and to measure HCV RNA in anti-
HCV-positive patients in whom interferon is contemplated.
Alpha-interferon therapy
Preliminary therapeutic trials of alpha-interferon indicated
that a proportion of patients may respond to treatment with
this agent. Larger, placebo-controlled studies have indicated
that approximately 50% of patients will have normal serum
aminotransferase activity after treatment courses of alpha-
interferon of approximately 3 million units three times a week
for 6 months.50.51
Serum HCV RNA may become undetectable in patients
after4 - 8 weeks of alpha-interferon treatment in patients
who respond, but an undetectable HCV RNA at the end of
treatment does not preclude relapse in patients.
However, after stopping treatment after 6 months, one-
half of the responsive patients will promptly relapse. Serum
aminotransferase levels usually increase in patients who are
HCV RNA positive at the end of therapy, although in some
cases the relapse may be delayed for several months.52 Our
studies at the Royal Free Hospital indicate that 20% of
patients have a prolonged response to therapy and do not
again develop elevated serum aminotransferase activity. 53
These patients also remain negative for HCV RNA.
There is most information about 3 MU three times a week
given for 6 months. It is not yet clear whether this dose is
optimal. Other regimens are being evaluated, and there is a
suggestion that higher doses may be beneficial. 54 Initiating
therapy with a somewhat higher dose of 15-18 million units
per week, and prolonging therapy for a year may result in
lower relapse rates; in a Japanese study of alpha-2b, it was
concluded that 10 MIU of interferon administered 6 days a
week for 2 weeks followed by three times a week for an
additional 12 weeks produces the highest rate of both
biochemical and virological responses to interferon therapy
in patients with chronic HCV.56 However, relapses still Occur
after higher doses, and the side-effects are greater at higher
doses. The cost of 6 months of treatment is at least R7 500.
Treatment should not be continued beyond 3 months in
patients who do not have reduced levels of serum ALT.
Responsive patients usually exhibit histological
improvement, and may have a decrease in collagen III
propeptide concentrations. 56
Unfortunately responsiveness to alpha-interferon remains
somewhat unpredictable. Factors which predict a greater
likelihood of response are now being studied. Multivariate
analyses of several pre-treatment parameters indicate that
patients without cirrhosis are more responsive to interferon,
and are more likely to have a sustained response. The
influence of genotypes of hepatitis C is of considerable
interest at present, as is the association between lower
levels of viraemia and response. In Japanese studies on
genotypes, it has become apparent that genotype 11
(Okamato or Simmonds 1b), the major genotype in Japan, is
associated with a poor response to interferon therapy.57.58
Similar differences in European patients have been reported.
However, (Okamato) genotype III (Simmonds 2a) is sensitive
to interferon in a high proportion of patients. Patients with
diverse circulating quasispecies may be less responsive to
therapy than those with a single major species. Improved
responses have been observed in patients with lower levels
of circulating HCV RNA.59 Unfortunately, the issue remains
complex: there is not yet a standardised system for
quantitating concentrations of HCV RNA in serum. Also,
these factors may be interdependent, as particular viral
strains may replicate at higher efficiency than others.
Genotyping and HCV RNA quantitation are not generally
available to clinicians. However, when serotyping becomes
available together with quantitation of HCV RNA, clinicians
may be able to rationalise the use of interferon and the dose
required.
When can treatment be considered successful? These
criteria vary, but it is reasonable to infer that those patients
with normal serum ALT a year after stopping interferon
treatment, and negative for HCV RNA a year after stopping
therapy, with histologically improved disease activity and
perhaps a normal serum procollagen III peptide
concentration, have had a good response. HCV antigens
may be cleared from the liver with successful treatment. 5O
Some patients have a sustained response to treatment; a
small proportion (approximately 10 - 20%) of these patients
may be HCV RNA-positive, but appear to have a higher
probability of later relapse off therapy. Others have a
transient response, have normal serum ALT on treatment,
and relapse soon after treatment is stopped. Other patients
may have a partial response with improvement but not
normalisation of the serum aminotransferases. Unfortunately
a proportion of patients may have a good initial response to
treatment, but then the ALT activity rises again despite
continuing treatment; it is possible that some patients
develop neutralising interferon antibodies. The timing of
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antibody development may be a factor in explaining the
course of responsive patients who do develop neutralising
antibodies.21 Continuing interferon with a second course of
treatment with a different interferon may be useful in some
patients. Only a small number of patients have been
reported, however. The significance of response to a
different interferon after unsuccessful treatment with a first
interferon is less certain.
Other patients do not respond to treatment, and no
improvement in serum ALT activity can be discerned. Some
patients may actually worsen on treatment with interferon,
and develop increased serum aminotransferases. A positive
anti-HCV antibody in patients with auto-immune disease
remains a pitfall in diagnosis, which has implications for
treatment 6 ' Such patients require confirmation by
immunoblot assay, or HCV RNA, as they may optimally
require corticosteroid therapy rather than alpha-interferon 61
It is possible that such patients have an underlying auto-
immune status associated with hepatitis C and exacerbated
by interferon treatment. For such patients, and for patients
who do not respond to treatment, ribavirin may be an
alternative.
Immunosuppressed patients and patients with HIV may
respond although long-term responsiveness is uncertain.
This is of particular importance in liver transplant patients.
Ribavirin
Ribavirin is a synthetic guanosine nucleotide analogue,
which possesses a broad spectrum of activity against both
DNA and RNA viruses in vitro and in vivo."" Efficacy has
been demonstrated in several viral diseases. The drug exerts
its action after intracellular phosphorylation to mono-, di-
and triphosphate nucleotides. The precise mode of action
probably includes perturbation of intracellular nucleoside
triphosphate pools, interference with the formation of the 5'
cap structure of viral mRNA by competitive inhibition of both
guanyltransferase- and methyltransferase-capping enzymes,
direct inhibition of the viral mRNA polymerase complex, and
possibly enhancement of macrophage inhibition of viral
repl ication.
The pharmacokinetics of ribavirin have been studied. The
bio-availability of oral formulations has been calculated at
19 - 65% (compared with intravenous administration). The
distribution half-life is 1 - 3 hours, but the terminal half life is
prolonged (27 - 52 hours), perhaps due to sequestration
within red cells and other tissues. Ribavirin is concentrated
10 - 50-fold in red blood cells, and crosses the blood-brain
barrier. Peak plasma levels range from 54 uM to 13 uM after
single oral doses of 600 - 2 400 mg. The excretion of the
drug is predominantly renal.
The major side-effects of the drug that have been
reported include anaemia, a metallic taste, dry mouth,
flatulence, dyspepsia, nausea, headaGhes, irritability,
emotional lability, fatigue, insomnia, skin rashes and myalgia.
Mild reversible anaemia is common. Modest increases in
uric acid have been reported.
Studies of ribavirin in hepatitis C infection
In an open-label study in Sweden, in which ribavirin was
prescribed to 10 patients with chronic hepatitis C (1 000 -
1 200 mg/day) for 12 weeks, median serum AST levels
declined, but rose to pre-treatment levels upon completion.53
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A small study, using escalating doses of ribavirin
(600 - 1 200 mg) showed a somewhat slower fall in serum
aminotransferases, perhaps reflecting the lower starting
dose of ribavirin."" There was a significant decrease in
geometric mean titres of HCV RNA. At the Royal Free
Hospital, we have treated 40 patients with chronic hepatitis
C.GS Thirty-eight per cent had normal ALT during treatment,
but a further one-third had only a 50% decline in ALT. The
remaining third were not responsive. The time course of
normalisation of ribavirin is slower (mean time to normal -
5,5 months) in patients with biochemical improvement.
Despite the significant improvement in serum ALT, we have
not observed a marked decline in serum HCV
concentrations. Further controlled trials to assess response
and relapse rates are warranted, and a multicentre placebo-
controlled trial of ribavirin for hepatitis C is now in progress.
Studies of ribavirin and alpha-interferon used sequentially or
together are also indicated, as preliminary reports indicate
that the combination of treatment is associated with higher
response rates than interferon alone. The multicentre
placebo-controlled trial of ribavirin for hepatitis C is now in
being analysed.
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A. R. Bird, B. J. Gibbs
Transmission of hepatitis viruses has been recognised as an
undesirable effect of blood transfusion since the 1940s,
when large outbreaks occurred following inoculation with a
yellow fever vaccine which contained pooled human plasma.
Further reports followed of jaundice occurring several
months after transfusions with blood or plasma.' It was also
noted in studies in the UK that the incidence of icteric
hepatitis increased relative to the number of units
transfused!
After the discovery of the Australia antigen in 1965, its
recognition as a marker of hepatitis B virus (HBV) infection
and its association with post-transfusion hepatitis (PTH), the
subsequent introduction of screening tests for this antigen in
the early 1970s led to a marked decrease in the incidence of
PTH_ However, despite increasingly sensitive testing
methods for hepatitis B surface antigen (HBsAg), as it
subsequently became designated, viral hepatitis was still
considered the commonest lethal complication of blood
transfusion.' It was clear that there were still a number of
cases of PTH that were due neither to hepatitis A virus nor
to HBV, and the term 'non-A, non-B hepatitis' (NANBH) was
coined.
The introduction of molecular techniques enabled clones
to be derived·from the genome of an agent associated with
transfusion-transmitted NANBH,3 and the proteins derived
from these clones were then used to develop nn enzyme-
linked immunosorbent assay (ELlSA)' to detect antibodies to
this virus, now termed hepatitis C virus (HCV). This ELlSA is
now used in most developed countries to screen for HCV
antibodies.
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